The CDF's willingness to pay value is £223,627 per QALY, of which 74% have a cost-benefit ratio of more than £50,000. This shows that the existence of CDF itself is to cover the cost of treatment beyond the traditional cost-benefit limit.
The CDF's willingness to pay is £223,627 per QALY, of which 74 per cent are cost-effective for medicines over £50,000. This suggests that the CDF itself exists to pay for treatment that exceeds traditional cost-benefit limits.
The value of willingness to pay of CDF is 223627 per QALY, of which 74% have a cost-benefit ratio of over 50000. This suggests that CDF itself exists to pay for treatment beyond the traditional cost-benefit limit.